Biocon initiates clinical study of Itolizumab for ulcerative colitis in India

This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study

Peter Bains appointed Additional Director of Biocon

He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels

Biocon Biologics elevates Shreehas Tambe as MD & CEO

Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.

Lonza collaborates with AbTis to extend Bioconjugation capabilities

Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox

Biocon Biologics completes acquisition of Viatris' Global Biosimilars Business

To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan

Biocon enters commercialization agreement with Zentiva

Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe

Biocon Q2FY23 net profit slips 10% to Rs 168 Cr; Revenue up 26%

Biocon Biologics features on ASIA IP ELITE List 2022

This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list

Lonza and Singzyme to accelerate development of Bioconjugates

Through the collaboration, Lonza will gain access to Singzyme’s enzymatic conjugation platform enabling the site-specific binding of payloads with peptidic linkers to proteins of interest

Biocon ranks No. 8 in ‘Global Top Employers’ by Science magazine

The company has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees’